Updates in Small Interfering RNA for the Treatment of Dyslipidemias
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Updates in Small Interfering RNA for the Treatment of Dyslipidemias
Authors
Keywords
-
Journal
Current Atherosclerosis Reports
Volume 25, Issue 11, Pages 805-817
Publisher
Springer Science and Business Media LLC
Online
2023-10-04
DOI
10.1007/s11883-023-01156-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease
- (2023) Toshiyuki Nishikido Cardiovascular Diabetology
- APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism
- (2023) Antonina Giammanco et al. Current Atherosclerosis Reports
- ORION-3: delivering lipid lowering treatment for longer
- (2023) Stephen J Nicholls Lancet Diabetes & Endocrinology
- Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial
- (2023) Kausik K Ray et al. Lancet Diabetes & Endocrinology
- Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE
- (2023) Prakriti Gaba et al. CIRCULATION
- Hypocholesterolaemic treatment in coronary unit: from statins to anti PCSK9 therapies and bempedoic acid
- (2023) Nicola Ferri et al. EUROPEAN HEART JOURNAL SUPPLEMENTS
- Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors
- (2023) Catherine M Spagnuolo et al. EXPERT OPINION ON PHARMACOTHERAPY
- The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia
- (2023) Zhu Luo et al. Journal of Clinical Lipidology
- Clinical Trial Design for Lipoprotein(a)-Lowering Therapies
- (2023) Waqas A. Malick et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- siRNA targeting ANGPTL3 stands in the spotlight for lipid-lowering therapy
- (2023) Bo Hu et al. Molecular Therapy-Nucleic Acids
- Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study
- (2023) Kausik K. Ray et al. The Lancet Regional Health Europe
- New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing
- (2023) Reindert F. Oostveen et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Independent Causal Effect of Remnant Cholesterol on Atherosclerotic Cardiovascular Outcomes: A Mendelian Randomization Study
- (2023) Eliano P. Navarese et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany
- (2023) U. Makhmudova et al. Clinical Research in Cardiology
- RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts
- (2023) Gerald F. Watts et al. NATURE MEDICINE
- Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factor
- (2023) Marlys L. Koschinsky et al. PHARMACOLOGICAL RESEARCH
- Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment
- (2022) David Kallend et al. Journal of Clinical Lipidology
- Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)
- (2022) Michael J. Koren et al. NATURE MEDICINE
- Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia
- (2022) M Doortje Reijman et al. European Journal of Preventive Cardiology
- Study Design and Rationale for the OCEAN(a)-DOSE (Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction-DOSE Finding Study) Trial
- (2022) Michelle L. O'Donoghue et al. AMERICAN HEART JOURNAL
- Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease
- (2022) David A. Rider et al. ATHEROSCLEROSIS
- Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70
- (2022) Brian A. Bergmark et al. CIRCULATION
- Small interfering RNA (siRNA): discovery, pharmacology and clinical development – an introductory review
- (2022) Priyanga Ranasinghe et al. BRITISH JOURNAL OF PHARMACOLOGY
- An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study
- (2022) David Kallend et al. CTS-Clinical and Translational Science
- Lp(a): a New Pathway to Target?
- (2022) Nick S. Nurmohamed et al. Current Atherosclerosis Reports
- Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
- (2022) Florian Kronenberg et al. EUROPEAN HEART JOURNAL
- Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9
- (2022) Nicola Ferri et al. PHARMACOLOGICAL RESEARCH
- Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials
- (2022) Wolfgang Koenig et al. CARDIOVASCULAR DRUGS AND THERAPY
- PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
- (2022) Stefano Carugo et al. Current Atherosclerosis Reports
- Inclisiran and cardiovascular events: a patient-level analysis of phase III trials
- (2022) Kausik K Ray et al. EUROPEAN HEART JOURNAL
- Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
- (2022) Kausik K Ray et al. EUROPEAN HEART JOURNAL
- Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease
- (2022) Berit Storgaard Hedegaard et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
- (2022) Michelle L. O’Donoghue et al. NEW ENGLAND JOURNAL OF MEDICINE
- Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
- (2022) Aruna Das Pradhan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review of recent clinical trials and their impact on the treatment of hypercholesterolemia
- (2022) Johnathon Seth Parham et al. PROGRESS IN CARDIOVASCULAR DISEASES
- Targeting ANGPTL3 by GalNAc-conjugated siRNA ANGsiR10 lowers blood lipids with long-lasting and potent efficacy in mice and monkeys
- (2022) Jue Wang et al. Molecular Therapy-Nucleic Acids
- Lipid Lowering Drugs: Present Status and Future Developments
- (2021) Massimiliano Ruscica et al. Current Atherosclerosis Reports
- Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis
- (2021) R. Scott Wright et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Long-term fasting improves lipoprotein-associated atherogenic risk in humans
- (2021) Franziska Grundler et al. EUROPEAN JOURNAL OF NUTRITION
- Global epidemiology of dyslipidaemias
- (2021) Angela Pirillo et al. Nature Reviews Cardiology
- The Limitless Future of RNA Therapeutics
- (2021) Tulsi Ram Damase et al. Frontiers in Bioengineering and Biotechnology
- Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
- (2021) Henry N Ginsberg et al. EUROPEAN HEART JOURNAL
- Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
- (2021) Brooke A Anderson et al. NUCLEIC ACIDS RESEARCH
- N-Acetyl Galactosamine Targeting: Paving the Way for Clinical Application of Nucleotide Medicines in Cardiovascular Diseases
- (2021) Erik A.L. Biessen et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association
- (2021) Gissette Reyes-Soffer et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The dawn of a new era of targeted lipid-lowering therapies
- (2021) Lale Tokgözoğlu et al. EUROPEAN HEART JOURNAL
- Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies
- (2021) Carlota Oleaga et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Lipoprotein(a): Knowns, unknowns and uncertainties
- (2021) Massimiliano Ruscica et al. PHARMACOLOGICAL RESEARCH
- Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia
- (2020) Massimiliano Ruscica et al. PHARMACOLOGICAL RESEARCH
- Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia
- (2020) G. Kees Hovingh et al. CIRCULATION
- Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation
- (2020) Johan G. Schnitzler et al. CIRCULATION RESEARCH
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evinacumab for Homozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins
- (2020) Mie Balling et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Treating Disease at the RNA Level with Oligonucleotides
- (2019) Arthur A. Levin NEW ENGLAND JOURNAL OF MEDICINE
- Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry
- (2019) Kornelia Kotseva et al. European Journal of Preventive Cardiology
- Use of lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. Don P. Wilson, MD, on behalf of the Writing group
- (2019) Don P. Wilson et al. Journal of Clinical Lipidology
- A NEW DAWN FOR MANAGING DYSLIPIDEMIAS: THE ERA OF RNA-BASED THERAPIES
- (2019) C. Macchi et al. PHARMACOLOGICAL RESEARCH
- Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels
- (2019) Kausik K. Ray et al. JAMA Cardiology
- Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies
- (2019) R. Scott Wright et al. MAYO CLINIC PROCEEDINGS
- HEART UK consensus statement on Lipoprotein(a): A call to action
- (2019) Jaimini Cegla et al. ATHEROSCLEROSIS
- RNA-Targeted Therapeutics
- (2018) Stanley T. Crooke et al. Cell Metabolism
- Impact of Lipids on Cardiovascular Health
- (2018) Brian A. Ference et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- ANGPTL3 Deficiency and Protection Against Coronary Artery Disease
- (2017) Nathan O. Stitziel et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
- (2017) Frederick E. Dewey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates
- (2017) Jayaprakash K. Nair et al. NUCLEIC ACIDS RESEARCH
- Site-Specific Modification Using the 2′-Methoxyethyl Group Improves the Specificity and Activity of siRNAs
- (2017) Xinyun Song et al. Molecular Therapy-Nucleic Acids
- Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease
- (2016) William Herrington et al. CIRCULATION RESEARCH
- Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
- (2016) Michael G. Silverman et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors
- (2016) Philip L.S.M. Gordts et al. JOURNAL OF CLINICAL INVESTIGATION
- Structure, function, and genetics of lipoprotein (a)
- (2016) Konrad Schmidt et al. JOURNAL OF LIPID RESEARCH
- Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
- (2014) Jayaprakash K. Nair et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
- (2014) Anders Berg Jørgensen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
- (2013) Kevin Fitzgerald et al. LANCET
- Delivery materials for siRNA therapeutics
- (2013) Rosemary Kanasty et al. NATURE MATERIALS
- Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
- (2008) M. Frank-Kamenetsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started